Commentary on ZD1839 (Iressa) in non small cell lung cancer

Lung Cancer

Volumn 40, Issue 1, 2003, Pages 77-78

  Ranson, M ^a   Thatcher, N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; PACLITAXEL;

ADENOCARCINOMA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; LUNG NON SMALL CELL CANCER; NOTE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 0037377662     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00041-2     Document Type: Note

References (11)

1. Ranson H., Hammond L., Ferry D., et al. ZD1839, a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumours: results of a phase I trial. J. Clin. Oncol. 20:2002;2240-2250.
2. Negoro S., Nakagawa K., Fukuoka M., et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 in Japanese patients with various solid tumours. Proc. Am. Soc. Clin. Oncol. 20:2001;324a.
3. Baselga J., Rischin D., Ranson M., et al. Phase I phamacokinetic and pharmacodynamic trial of ZD1839 (Iressa), a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302.
4. Kris M., Herbst R., Rischin D., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839, a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor. Lung Cancer. 29:(Suppl. 1):2000;72.
5. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: 1188a.
6. Douillard J.Y., Skarin A., Baselga J., et al. Improvement in disease-related symptoms and quality of life for advanced non-small cell lung cancer (NSCLC) patients treated with ZD1839 in IDEAL 1 and 2. Ann. Oncol. 13:(Suppl. 5):2002;480a.
7. Kris M., Natale R., Herbst R., et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer who had tailed platinum and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 21:2002;1166a.
8. Natale R.B., Skarin A.T., Maddox A.M., et al. Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 (Iressa) in IDEAL 2. Proc. Am. Soc. Clin. Oncol. 21:2002;1167a.
9. Ranson M., Mansoor W., Jayson G. ZD1839 (Iressa): a selective EGFR-TK inhibitor. Expert Rev. Anticancer Ther. 2:2002;161-168.
10. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT 1). Ann. Oncol. 13:(Suppl. 5):2002;40a.
11. Johnson D.H., Herbst R., Giaccone G., et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann. Oncol. 13:(Suppl. 5):2002;468a.